Genexine has appointed Choi Jae-hyun as the new representative director, transitioning from the previous single directorship of Hong Seong-jun to a dual directorship of Hong Seong-jun and Choi Jae-hyun, according to a statement on the 27th.
The company decided to change the directorship structure to strengthen its research and development expertise at a board meeting held after the regular shareholders' meeting.
Accordingly, Representative Hong Seong-jun will oversee the management and business development institutional sector, while new Representative Choi Jae-hyun will manage all R&D-related sectors, including the bio-research institute and clinical development division.
Choi, who joined Genexine last year, earned his bachelor's and master's degrees in microbiology from Seoul National University and completed his doctoral studies at the University of Toronto in Canada. He then gained experience in the development of bio-pharmaceuticals at LG CHEM, Samsung Electronics, and companies such as Trillium Therapeutics and Abivax.
Choi developed a next-generation targeted protein degradation bioPROTAC platform based on the PROTAC research expertise he gained at Abivax, a specialty company in targeted protein degradation. Currently, Genexine is researching various candidates, including the lung squamous cell carcinoma treatment 'GX-BP1' and atopic dermatitis and cancer treatment 'GX-BP2', utilizing the bioPROTAC platform.
Choi said, "As I promised when I joined Genexine, I will work hard to establish Genexine as a global leader in bioPROTAC platform technology and achieve technology exports."